News & Perspective

Oct 27, 2014

Oct 27, 2014

CSL-Novartis deal includes US cell-based flu vaccine plant

The $275 million deal will make the company the second leading player in the $4 billion global flu vaccine market.

Aug 06, 2009

Aug 06, 2009

WHO says H1N1 vaccine process won't sacrifice safety

(CIDRAP News) – The World Health Organization (WHO) said today that the fast-tracking of vaccines for pandemic H1N1 influenza won't compromise safety, while acknowledging that clinical data will be limited when the first doses are administered.

Apr 05, 2007

Apr 05, 2007

Firm seeks US license for seasonal flu vaccine

(CIDRAP News) – CSL Biotherapies, the US branch of an Australian vaccine producer, announced this week it has applied for Food and Drug Administration (FDA) approval to market a seasonal influenza vaccine in the United States.